

Message from the chief executive officer

Dear Shareholders,

Last year, we informed you of the strategic decision to refocus our activities on the high added value markets of health, nutrition, and cosmetics. In one year, we have passed several steps in this direction:

- We have completed the integration of our subsidiary DEINOBIOTICS and advanced in the development of an antibiotic candidate of innovative structure. We are working on the discovery and development of other molecules;
- We have gone through all the steps planned for the development of the first carotenoid from our DEINOCHEM program, whose commercial launch is scheduled for the first half of 2018;
- We have signed a partnership for the development of another active ingredient for cosmetics with GREENTECH;
- Our two collaborative animal nutrition programs are progressing according to plan.

2018 will be another important year for DEINOVE, with the challenge of launching our first molecules and the advancement of our AGIR project, which has just received € 14.6 m of funding from the Investments for the Future Program. We continue our human and technological structuring with the strengthening of our screening, extraction and analysis capabilities, as well as a program to expand our library of rare bacterial strains, a key asset of our development.

In order to maintain control over our development and to enable us to make the necessary investments where appropriate, we have convened an Extraordinary General Assembly, which must approve the renewal of capital increase authorizations. We sincerely hope that many of you will vote, thus marking your commitment to us. 2018 represents for DEINOVE the transition to the commercial status, materializing several years of research. We continue to rely on you.

Emmanuel PETIOT, Chief Executive Officer

Be part of the life of your Company

Vote at the Extraordinary General Meeting on December 4, 2017

Why hold a General Meeting?

The General Meeting is called upon to renew the Company's usual capital increase authorizations. The goal is to ensure that your company always has all the tools it needs to grow.

Why vote?

As a DEINOVE shareholder, you are involved in the development of the Company. You can also participate in important decisions by exercising your right to vote in the Assembly.

How to vote?

- In person on the day of the General Meeting: send us an application for an admission card accompanied by the Certificate of Participation.
- By returning a postal ballot accompanied by the Certificate of Participation.

Deadline: November 30

Do not forget your Certificate of Participation!

Bearer shareholders, to vote at the GM (in person, by mail or by proxy), you must provide a Certificate of Participation stating the number of DEINOVE shares you hold and therefore your voting rights (Art. R.225-85 of the French Commercial Code). This certificate must be issued by the bank where the securities are registered in bearer form. This formality may require some time. Consult with your account manager or customer services department to validate the specific terms and conditions for issuing this certificate by your bank.

Find all the documents relating to the General Meeting on our website www.deinove.com

January 2017, first patented antibiotic structure by **Deinobiotics**, a wholly owned subsidiary of Deinove

April, second step in the Animal Nutrition Program with Avril: potential of the strains validated, first patent in animal nutrition, issued in China

May, first step of the Animal Nutrition Program with **Flint Hills Resources**: selection of several strains meeting their criteria


September, funding of € 14.6 million granted to the **AGIR project** (new antibiotics) by the PIA

October, proprietary carotenoid program: production of the active ingredient in its commercial form for cosmetics, stability of the validated product, and initiation of marketing contacts

March, several dozen strains identified for applications in cosmetics and health; partnership with **Greentech** to market new active ingredients for cosmetics, the first in 2018

July, propriety **carotenoid program**: phase II of the industrialization process; selection of the first molecule for industrial scale production in 2018; achievement of above-target performance > anti-aging active ingredient to be marketed in 2018

December 4, Extraordinary General Meeting



PROPRIETY CAROTENOID PROGRAM: PROGRESS

\$ 1.8 BILLION

Global market for carotenoids in 2019

2018

Launch of the first DEINOVE carotenoid for cosmetics

Carotenoids, molecules with multiple properties of interest

More than 1,200 kinds of different carotenoids exist. Some are well known, such as beta-carotene, often used as a dietary supplement for its antioxidant and photoprotective properties. Others are used in food and feed for their coloring properties. They are also found in cosmetic or medical applications.

Some are produced by extraction from tomatoes (lycopene) or paprika (capsanthin), or by bioproduction from algae (astaxanthin) or micro-organisms (beta-carotene). Most of the production, however, comes from chemical synthesis from petroleum derivatives.

As the demand for natural ingredients increases, bio-based solutions remain limited by high production costs, which leaves room for the development of more competitive alternatives, such as that of DEINOVE.

A first innovative carotenoid produced from Deinococci on the market in 2018

2018 will be the year of DEINOVE's first product launch. It will be a product unparalleled on the market today, intended initially for cosmetic applications.

DEINOVE has conducted functional tests to confirm the properties of the molecule. Its antioxidant and healing properties are particularly attractive for anti-aging care, a major and fast-growing sector. The tests


Progress in 2017

- Validation of the antioxidant and healing properties of a first compound
- Optimization of production conditions and yields
- Validation of extraction and formulation processes
- Definition of the industrial production process and choice of subcontractors

Next steps

- First batch production on an industrial scale
- Packaging of samples
- Clinical tests (on skin explants and then by consumers) to confirm the efficacy
- Commercial launch

have demonstrated the product's safety. At the same time, technical developments have continued, resulting in a formulation adapted to market requirements and guaranteeing product stability over time. DEINOVE has opted for a vegetable oil-based formulation, particularly suitable for incorporation into care creams. The product will be launched commercially in the first semester of 2018. Contacts have already been made with several market players, brands, and ingredient distributors. The initial feedback is positive.



The new screening platform makes it possible to evaluate the properties of each molecule internally: antioxidant effect, healing, whitening, etc.

OVERVIEW: OUR OTHER PROGRAMS

AVRIL

Animal Nutrition Program launched in 2014. Now in Phase III: validation of the selected strain, tests in real conditions of use, validation of industrial production processes and regulatory procedures.

FLINT HILLS RESOURCES

Animal Nutrition Program launched in 2015. Now in Phase II: production for tests in real conditions, evaluation of beneficial effects, economic analyzes.

GREENTECH

Cosmetic program launched in 2017. Phase I: selection of strains, efficacy tests, and production of the retained bacterial extract. Market launch planned for 2018.

THE «AGIR» PROJECT AIMED AT DISCOVERING NEW ANTIBIOTICS RECEIVES SUPPORT FROM 'Investments for the Future' Program

2 PATENTS

filed on an innovative antibiotic structure

10 MILLION LIVES

to save each year

€ 14,6 MILLION

of public funding

Challenge

The World Health Organization (WHO) has placed the fight against antimicrobial resistance as a global priority. High proliferation of resistant and multi-resistant bacteria could cause 10 million deaths annually by the year 2050, which is more than cancer today (8 million deaths per year). In February 2017, the WHO published a list of the 12 bacteria families the most threatening to human health.

“Antimicrobial resistance is like a tsunami in slow motion. It is a global crisis that we face urgently. In 50 years, only two new classes of antibiotics have appeared on the market. With so few antibiotics in the pipeline, the world is heading towards a new era where a simple infection will have fatal consequences.

Dr Margaret Chan,
Director-General of WHO, Sept. 2016

The AGIR project Antibiotics against infectious germ resistance

No innovative antibiotic has been placed on the market since 2010, and only three were placed during the previous five years. While bacteria are among the most successful antibiotic producers of the living world, research so far has focused on a

range of microorganisms, significantly limiting the opportunities to discover new antibiotics effective against resistant bacteria.

Run by the DEINOVE group and the INSTITUT CHARLES VIOLLETTE (ICV), the AGIR project aims to discover new antimicrobials through an innovative discovery strategy.

The AGIR program builds on the common experience of its partners and their advanced technologies to create a platform for the selection, identification, and development of new antimicrobial compounds of natural origin.

It includes two integral elements:

- Boost the development of the discovery platform: enrich the strain bank in a targeted way, adjust the growth conditions to induce antibiotic production, implement a fine screening of the antimicrobial activities in a sample, isolate and identify the molecules of interest;
- Integrate the complementary technologies that optimize leads and develop the fermentation processes: the unique trio - genetic engineering, enzymology, and medicinal chemistry - will allow the partners to optimize the expression of microorganisms and obtain molecules of the highest performance.

The AGIR project represents a total investment of € 25 m over five years. Selected by the 'Investments for the Future' Program, steered by the General Commission for investment, and operated by Bpifrance, it will receive € 14.6 m of funding over the period.

THE AGIR PROJECT PARTNERS

A consortium with complementary skills and added-value synergies

DEINOBIOTICS

Expertise: discovery and development of drug candidates

Roles: scientific strategy, lead optimization (medicinal chemistry), preclinical and clinical development

DEINOVE

Expertise: biodiversity, genetic, metabolic, and fermentation engineering

Roles: development of the pipeline, lead optimization (genetic engineering), batch production

INSTITUT CHARLES VIOLLETTE

Expertise: innovation in fermentation and enzyme engineering

Roles: characterization, lead optimization (enzyme engineering), process improvement

DEINOBIOTICS has worked for several years with the ICV to analyze DEINOVE's strains and discover new antimicrobials.

A first lead, DNB101, has undergone requests for patents for its original antibiotic structure. This molecule is being optimized, and other molecules are currently under investigation.

This successful collaboration and the experience gathered are at the source of the AGIR program.

SHAREHOLDERS' MEMENTO

Management



Emmanuel PETIOT
Chief Executive Officer



Dominique LE BELLER
Chief Executive Officer of
DEINOBIOTICS



Marie BEZENGER
Director of Operations



Julien COSTE
Director of Administration and
Finance



Sébastien ENAULT
Head of Business Development



Georges GAUDRIALT
Scientific Director



Coralie MARTIN
Head of Communication and
Investor Relations



Johane RINALDI
Head of Human Resources

“ DEINOVE capitalizes on the scientific excellence of its teams, its cutting-edge technological platform, and the richness of its collection of rare microorganisms to accelerate revenue generation.

Dr Charles WOLER, *Chairman of the Board of Directors*


DEINOVE Stock

PRICE ON 31.10.17	€ 1,75
MARKET CAP	€ 18 M
52-WEEKS HI-QW.....	€ 1,65-€ 2,55
2017 AVERAGE DAILY VOLUME.....	58,000 shares/day
MARKET	Euronext Growth®
ISIN	FR0010879056
MNEMO	ALDEI

RECEIVE ALL OUR
INFORMATION DIRECTLY
BY EMAIL!

Send us your details or sign up at
www.deinove.com

BREAKDOWN OF CAPITAL AT 30.06.017 (diluted basis)



CONTACT-US

Coralie MARTIN

Investor relations

Tel.: +33 448 19 01 60

Cap Sigma / ZAC Euromédecine II
1682 rue de la Valsière
34790 Grabels FRANCE

E- mail :

coralie.martin@deinove.com

More information at
www.deinove.com

Analyst consensus

Broker	Target price	Date
Edison	€ 4,4	01/09/2017
Invest Securities	€ 4,4	30/09/2017
Portzamparc	€ 5,6	05/10/2017

FOLLOW US ON SOCIAL MEDIA



www.twitter.com/Deinove



www.linkedin.com/company/deinove